Tesamorelin
Tesamorelin is a peptide, indexed here under GHRH analogues.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | GHRH analogues |
| CAS registry number | 218949-48-5[1] |
| PubChem CID | 16137828[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C221H366N72O67S[1] |
| Molecular weight | 5136 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Tesamorelin is a growth hormone-releasing factor analogue, identified by the development code TH9507 in a 2010 Journal of Clinical Endocrinology and Metabolism trial report. The retrieved clinical literature is concentrated in one population: HIV-infected patients with abdominal fat accumulation, reported in 2008 in AIDS, in 2010 in the Journal of Acquired Immune Deficiency Syndromes, and in 2014 in JAMA.
A 2019 Lancet HIV randomised double-blind trial reports effects on non-alcoholic fatty liver disease in HIV. This is the only member of this class in the dataset for which the FDA application register returned a current record.
[3, 4, 5, 6, 7]Reported mechanism
A growth hormone-releasing factor analogue acting at the GHRH receptor.
[3]Stated in the title of the cited 2010 Journal of Clinical Endocrinology and Metabolism trial report, which names it a growth hormone-releasing factor analog.
Targets named in the cited records: GHRH receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including BLA022505, marketed as EGRIFTA). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Tesamorelin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- TH9507
- Egrifta
Where this page sits
Research records
Cited research records for Tesamorelin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include Tesamorelin
Compounds indexed next to it
- Sermorelin — GHRH analogues
- CJC-1295 — GHRH analogues
- Octreotide — Endocrine and immune signalling peptides
Named targets in the cited records
Class page: GHRH analogues. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Tesamorelin?
Tesamorelin is a growth hormone-releasing factor analogue, identified by the development code TH9507 in a 2010 Journal of Clinical Endocrinology and Metabolism trial report. The retrieved clinical literature is concentrated in one population: HIV-infected patients with abdominal fat accumulation, reported in 2008 in AIDS, in 2010 in the Journal of Acquired Immune Deficiency Syndromes, and in 2014 in JAMA.
Which class is Tesamorelin indexed under?
Tesamorelin is indexed under GHRH analogues. GHRH analogues are peptides modelled on growth hormone releasing hormone, which act at the GHRH receptor on the anterior pituitary.
What does the FDA application register show for Tesamorelin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including BLA022505, marketed as EGRIFTA). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- PubChem Compound Summary for CID 16137828, Tesamorelin. PubChem, National Library of Medicine (2026). pubchem:16137828
- Drugs@FDA application register query for this compound, 1 application(s) returned: BLA022505. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:tesamorelin
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab (2010). pmid:20554713
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS (2008). pmid:18690162
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr (2010). pmid:20101189
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA (2014). pmid:25038357
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV (2019). pmid:31611038
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.